Skip to content

Extreme phenotype social jetlag study

Extreme phenotype social jetlag study - Extreme phenotype social jetlag study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56332
Enrollment
40
Registered
2022-08-30
Start date
2023-02-13
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 40 participants with prediabetes (FPG 6.1-7.0mmol/l) who have provided consent to be informed about future research will be identified in the New Hoorn Study Cohort in the measurement of 2021-2023. 20 of them having more than 1 hour of social jetlag and 20 of them having less than 1 hour of social jetlag.

Exclusion criteria

Exclusion criteria: Excessive alcohol use (>14 alcoholic consumptions per week) Having crossed more than 1 time zone in the month prior to participation Working shifts more than once per month Unable to give written informed consent

Design outcomes

Primary

MeasureTime frame
The first main outcome is glycaemic control, measured with fasting blood glucose levels, HbA1c levels, and 2h glucose levels after an oral glucose tolerance test, comparing those with and without social jetlag.

Secondary

MeasureTime frame
Additionally, to assess which factors mediate this association, we will assess physical activity, (para)sympathetic nervous systemactivity from ECGs and electrochemical skin conductance tests, the Dim Light Melatonin Onset (DLMO) in saliva samples, HPA-axisactivation from cortisol awakening reaction in saliva samples and visceral fat distribution.Physical activity and sleep times and phases will be measured using an activity tracker and a sleep measuring headband. Dietaryintake will be assessed from the central Hoorn Study visit (or the RISC of HOM study visit).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)